On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients 2 months of age and older.
SURVIVOR launches a new chapter when the Emmy Award-winning series returns on Wednesdays. Stranded in the beautiful islands of Fiji, these 18 determined new castaways…
Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.
FDA approves Ryoncil, the first MSC therapy to treat steroid-refractory acute graft-versus-host disease (SR-a GVHD) in pediatric patients 2 months of age and ol
A real-world study sought to measure survival outcomes against the results of a pivotal clinical trial on the effectiveness of durvalumab plus chemotherapy.
Dr. Toni K. Choueiri shares how hard work and focus keeps him from getting discouraged or giving up when times get hard.
Evan Y. Yu, MD, discusses how the goals of therapy for a patient with newly- diagnosed metastatic hormone-sensitive prostate cancer are to control disease progression,…
China has made significant strides in drug development over the past two decades, transitioning from being a producer of generic drugs to a…
2024 was a year of breakthroughs in cancer care, research and knowledge at Ohio State, where oncology experts look ahead to opportunities to innovate in…
On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory…
An abstract is unavailable.
